(Adds details throughout)
March 27 (Reuters) - Novocure NVCR.O said on Wednesday
that its cancer therapy met the main goal of a late-stage trial
testing it as a treatment for a type of lung cancer.
The therapy along with supportive care slowed the spreading
of cancer to the brain to 21.9 months compared to 11.3 months
for supportive care alone.
Novocure said it plans to submit the data to regulatory
authorities.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shounak
Dasgupta)
((Puyaan.Singh@thomsonreuters.com))